Study tests if lung cancer screening cuts smoking:
This article was originally published in Clinica
Executive Summary
A US team has been awarded $3.6m to find out whether CT screening for lung cancer will encourage cigarette smokers to give up the habit or if it will make them put off the decision even longer. In a 4,000-patient study headed by CT lung cancer screening leader Claudia Henschke, researchers from the Weill Medical College of Cornell University, New York, hope to show that CT screening can be effectively linked to smoking-cessation programmes to enhance the motivation for people to stop smoking. "We want to make screening programmes an economic and life-saving reality," said Dr Henschke. The new funds were made through matching grants of $1.8m respectively from the American Legacy Foundation and the UK's Medicsight Foundation. The study is scheduled to start in June.
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.